GLP-1 (glucagon-like peptide-1) is a hormone your small intestine releases after a meal. It’s part of the incretin system — the body’s way of coordinating digestion, insulin release, and satiety. GLP-1 medications are long-acting copies of this hormone, engineered to stay in the bloodstream for days instead of minutes.
The three core effects
1. They slow gastric emptying
Food leaves your stomach more slowly. You feel full faster and stay full longer. This is the main reason people on GLP-1s eat smaller portions almost automatically — and also the reason early nausea is so common.
2. They turn down appetite signaling in the brain
GLP-1 receptors exist in the hypothalamus and brainstem — regions that regulate hunger. Activating them reduces what users often describe as “food noise”: the constant background pull toward eating. Many patients report this is the biggest behavioral change, not the gut effect.
3. They boost insulin release — but only when needed
GLP-1 tells the pancreas to release insulin in response to elevated glucose. Because the effect is glucose-dependent, GLP-1s rarely cause hypoglycemia on their own (unlike sulfonylureas or insulin). They also suppress glucagon, the hormone that tells your liver to release stored sugar.
What makes tirzepatide different
Tirzepatide (Mounjaro, Zepbound) is a dual agonist — it hits both the GLP-1 receptor and the GIP receptor. GIP is another incretin hormone that, when paired with GLP-1, appears to:
- Improve insulin sensitivity beyond GLP-1 alone
- Increase energy expenditure modestly
- Possibly reduce nausea relative to GLP-1 mono-agonists at equivalent weight-loss doses
That combination is why tirzepatide outperformed semaglutide head-to-head in SURPASS-2 (diabetes) and SURMOUNT-5 (obesity).
Why the weight stays off only while you take it
GLP-1s don’t permanently rewire metabolism. They suppress hunger and slow digestion as long as the drug is in your bloodstream. When you stop, those effects fade, your body’s set-point defenses (lower leptin, higher ghrelin, lower resting metabolic rate after weight loss) reassert themselves, and most people regain a significant share of the lost weight.
This is why most clinicians now describe GLP-1s as chronic therapies — comparable to statins or blood pressure drugs, not a one-off course of antibiotics.
What this means for side effects
Almost every GLP-1 side effect traces back to the mechanism:
- Nausea, vomiting, constipation — slowed gastric emptying.
- Gallbladder disease — rapid weight loss + altered bile flow.
- Pancreatitis (rare) — incretins act on the pancreas.
- Muscle loss — driven by overall weight loss, not the drug itself; preventable with protein intake and resistance training.
See the side effects guide for practical management, and the safety overview for boxed warnings and contraindications.